Stockreport

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc.  (BFRI) 
PDF First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Dat [Read more]